Spots Global Cancer Trial Database for A Study of SGN-PDL1V in Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of SGN-PDL1V in Advanced Solid Tumors
Official Title: A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors
Study ID: NCT05208762
Study Description
Brief Summary: This study will test the safety of a drug called SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have four parts. Parts A and B of the study will find out how much SGN- PDL1V should be given to participants. Part C will use the dose found in Parts A and B to find out how safe SGN-PDL1V is and if it works to treat solid tumor cancers. In Part D, participants will be given SGN-PDL1V with pembrolizumab to find out how safe this combination is and if it works to treat solid tumor cancers.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States
University of California Davis, Sacramento, California, United States
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Karmanos Cancer Institute / Wayne State University, Detroit, Michigan, United States
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
South Texas Accelerated Research Therapeutics Mountain Region, West Valley City, Utah, United States
NEXT Oncology, Fairfax, Virginia, United States
Institut Jules Bordet, Anderlecht, Other, Belgium
University Health Network, Princess Margaret Hospital, Toronto, Other, Canada
McGill University Department of Oncology / McGill University Health Centre, Montreal, Quebec, Canada
Institut Curie, Paris cedex 05, Other, France
Institut Gustave Roussy, Villejuif, Other, France
Charite Universitatsmedizin Berlin, Berlin, Other, Germany
Istituto Europeo di Oncologia, Milano, Other, Italy
Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Other, Italy
Antoni Van Leeuwenhoekziekenhuis, Amsterdam, Other, Netherlands
Hospital Universitari Vall d'Hebron, Barcelona, Other, Spain
Institut Catala d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet), Barcelona, Other, Spain
START Madrid-CIOCC_Hospital HM Sanchinarro, Madrid, Other, Spain
Sarah Cannon Research Institute UK, London, Other, United Kingdom
The Royal Marsden Hospital, Surrey, Other, United Kingdom
Contact Details
Name: Medical Monitor
Affiliation: Seagen Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
